MCID: BCL017
MIFTS: 58

B-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for B-Cell Lymphoma

MalaCards integrated aliases for B-Cell Lymphoma:

Name: B-Cell Lymphoma 12 52 29 15 37
Lymphoma, B-Cell 52 43 39
B-Cell Lymphomas 74 15
B-Cell Lymphocytic Neoplasm 12
Lymphoma B-Cell 54

Classifications:



External Ids:

Disease Ontology 12 DOID:707
MeSH 43 D016393
NCIt 49 C27907 C3457
SNOMED-CT 67 1929004
ICD10 32 C85.1
UMLS 71 C0079731

Summaries for B-Cell Lymphoma

NIH Rare Diseases : 52 B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterized by abnormalities of the "B-cells" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. When present, signs and symptoms may include swollen lymph nodes in the neck, armpit, or groin; abdominal pain; fatigue; fever; night sweats; and/or weight loss. The underlying cause of B-cell lymphoma is poorly understood. However, the condition can be associated with genetic abnormalities, environmental factors , viruses , immunodeficiency states, and connective-tissue disorders . Treatment is based on many factors, including the severity of the condition and the associated signs and symptoms.

MalaCards based summary : B-Cell Lymphoma, also known as lymphoma, b-cell, is related to marginal zone b-cell lymphoma and primary mediastinal b-cell lymphoma. An important gene associated with B-Cell Lymphoma is MIR17 (MicroRNA 17), and among its related pathways/superpathways are NF-kappaB Signaling and MicroRNAs in cancer. The drugs Thiotepa and Decitabine have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Disease Ontology : 12 A non-Hodgkin lymphoma that has material basis in B cells.

Wikipedia : 74 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for B-Cell Lymphoma

Diseases in the B-Cell Lymphoma family:

T-Cell Lymphoma 1a

Diseases related to B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1234)
# Related Disease Score Top Affiliating Genes
1 marginal zone b-cell lymphoma 35.7 MALT1 IRF4 CCND1 BCL6 BCL10
2 primary mediastinal b-cell lymphoma 35.6 REL BCL6 BCL11A
3 diffuse large b-cell lymphoma 35.5 REL PASD1 PARP9 MYC MIR17 MDM2
4 primary cutaneous marginal zone b-cell lymphoma 35.5 MALT1 IRF4 BCL10
5 primary mediastinal large b-cell lymphoma 35.4 IRF4 BCL6
6 nodal marginal zone b-cell lymphoma 35.4 MALT1 BCL6
7 primary cutaneous diffuse large b-cell lymphoma, leg type 35.4 MYC IRF4
8 lymphoma, mucosa-associated lymphoid type 35.3 MYC MALT1 IRF4 CCND1 BCL6 BCL10
9 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 34.9 MYC BCL6
10 plasmablastic lymphoma 34.3 MYC BCL6
11 follicular lymphoma 34.1 MYC MIR17 IRF4 CCND1 BCL6 BCL10
12 lymphoma 33.3 REL PVT1 PASD1 PARP9 MYC MDM2
13 burkitt lymphoma 33.3 TP53COR1 PVT1 MYC IRF4 CCND1 BCL6
14 central nervous system lymphoma 32.4 MYC MALT1 BCL6
15 gastric lymphoma 32.4 MALT1 IRF4 BCL6 BCL10
16 chromosomal triplication 32.3 MALT1 BCL3
17 nodular lymphocyte predominant hodgkin lymphoma 32.3 CCND1 BCL6
18 lymphocytic leukemia 32.3 MYC HOTAIR CCND1 BCL3
19 lymphoma aids related 32.2 MYC BCL6
20 lymphoma, hodgkin, classic 32.1 REL PVT1 MIR20A IRF4 BCL6 BCL3
21 lung lymphoma 32.0 MALT1 IRF4 BCL6
22 lymphoma, non-hodgkin, familial 32.0 MYC MIR20A MIR17 MDM2 MALT1 IRF4
23 plasmacytoma 32.0 PVT1 MYC IRF4 CCND1
24 gastrointestinal lymphoma 31.9 MALT1 CCND1 BCL6
25 mantle cell lymphoma 31.8 MYC MIR17 MDM2 MALT1 MALAT1 GAS5
26 breast lymphoma 31.8 IRF4 BCL6
27 peripheral t-cell lymphoma 31.8 CCND1 BCL6 BCL3
28 leukemia 31.8 MYC HOTAIR GAS5 CCND1 BCL3 BCL11A
29 adult lymphoma 31.8 MYC IRF4 BCL6
30 adult t-cell leukemia 31.7 REL MYC IRF4
31 t-cell leukemia 31.6 REL MYC IRF4 GAS5 CCND1
32 orbit lymphoma 31.5 MALT1 BCL10
33 pediatric lymphoma 31.5 MYC IRF4 BCL6
34 plasma cell neoplasm 31.4 PVT1 MYC IRF4 CCND1 BCL6
35 mature b-cell neoplasm 31.3 PVT1 MYC MIR17 IRF4 CCND1 BCL6
36 alpha chain disease 31.3 MALT1 CCND1 BCL10
37 inflammatory myofibroblastic tumor 31.2 MYC MDM2 CCND1
38 testicular lymphoma 31.2 IRF4 BCL6
39 in situ carcinoma 31.2 MYC MIR17 CCND1
40 acute t cell leukemia 31.1 MYC MIR17 BCL10
41 leukemia, chronic lymphocytic 31.1 TP53COR1 REL MYC MIR20A MIR17 MDM2
42 sezary's disease 31.0 MYC MIR17 BCL10
43 retinoblastoma 30.9 MYC MDM2 MALAT1 HOTAIR CCND1
44 follicular lymphoma 1 30.8 BCL6 BCL10
45 lymphatic system cancer 30.8 MYC MIR17 IRF4 BCL6
46 retinitis pigmentosa 11 30.8 PVT1 MYC HOTAIR
47 liposarcoma 30.7 MYC MDM2 CCND1
48 leukemia, acute myeloid 30.7 TUG1 MYC MIR17 MDM2 MALAT1 HOTAIR
49 ductal carcinoma in situ 30.5 MYC MIR17 CCND1
50 squamous cell carcinoma 30.5 TUG1 MYC MALAT1 HOTAIR CCND1

Graphical network of the top 20 diseases related to B-Cell Lymphoma:



Diseases related to B-Cell Lymphoma

Symptoms & Phenotypes for B-Cell Lymphoma

Drugs & Therapeutics for B-Cell Lymphoma

Drugs for B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 495)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
2
Decitabine Approved, Investigational Phase 4 2353-33-5 451668
3
Lithium carbonate Approved Phase 4 554-13-2
4
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
5
Epirubicin Approved Phase 4 56420-45-2 41867
6 Liver Extracts Phase 4
7
Apatinib Phase 4 811803-05-1
8 Central Nervous System Depressants Phase 4
9 Tranquilizing Agents Phase 4
10 Psychotropic Drugs Phase 4
11 Antimanic Agents Phase 4
12 Antidepressive Agents Phase 4
13 Interleukin-2 Phase 4
14
Clarithromycin Approved Phase 3 81103-11-9 84029
15
Daunorubicin Approved Phase 3 20830-81-3 30323
16
Pixantrone Approved, Investigational Phase 3 144510-96-3
17
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
18
Metronidazole Approved Phase 3 443-48-1 4173
19
Mercaptopurine Approved Phase 3 50-44-2 667490
20
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
21 Orange Approved Phase 3
22
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
23
Acetaminophen Approved Phase 3 103-90-2 1983
24
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
25
Promethazine Approved, Investigational Phase 3 60-87-7 4927
26
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
27
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
28
Chlorambucil Approved Phase 3 305-03-3 2708
29
Acyclovir Approved Phase 3 59277-89-3 2022
30
Ribavirin Approved Phase 3 36791-04-5 37542
31
Palivizumab Approved, Investigational Phase 3 188039-54-5
32
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
33
Dalteparin Approved Phase 3 9005-49-6
34
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
35
Ofloxacin Approved Phase 3 82419-36-1 4583
36
Captopril Approved Phase 3 62571-86-2 44093
37
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
38
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
39
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
40
Piperacillin Approved Phase 3 66258-76-2 43672
41
Tazobactam Approved Phase 3 89786-04-9 123630
42
Vancomycin Approved Phase 3 1404-90-6 441141 14969
43
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
44
Rasburicase Approved, Investigational Phase 2, Phase 3 134774-45-1
45
Vinblastine Approved Phase 3 865-21-4 13342 241903
46
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
47
Metformin Approved Phase 3 657-24-9 14219 4091
48
Idarubicin Approved Phase 3 58957-92-9 42890
49
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
50
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754

Interventional clinical trials:

(show top 50) (show all 1947)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
2 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
3 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
4 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
5 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
6 A Prospective Cross-over Study Comparing the Effect of Sirolimus Versus Mycophenolate on Viral Load in Liver Transplant Recipients With Recurrent Chronic HCV Infection Completed NCT01134952 Phase 4 Mycophenolate to sirolimus switch
7 Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma. Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
8 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Recruiting NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
9 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03579082 Phase 4 Decitabine
10 Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma Recruiting NCT04152577 Phase 4 R2-combination chemotherapy;R-combination chemotherapy
11 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
12 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
13 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
14 Evaluation of Brain and Cognitive Changes in Older Adults With MCI Taking Lithium to Prevent Alzheimer Type Dementia Recruiting NCT03185208 Phase 4 Lithium Carbonate;Placebo oral capsule
15 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
16 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
17 Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for Chemotherapy-resistant or Refractory CD19+B Cell Lymphoma:a Double-arm, Single Center, Open-label Clinical Trial Not yet recruiting NCT02992834 Phase 4
18 Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Not yet recruiting NCT04134247 Phase 4 PD-1 combined with chemotherapy;chemotherapy
19 R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail Unknown status NCT00846157 Phase 3
20 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
21 Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study Unknown status NCT02777736 Phase 3 Methotrexate
22 A Multicenter, Randomized, Double-blind, Controlled, Phase III Study to Evaluate the Efficacy and Safety of IBI301 (Recombinant Chimeric Anti-CD20 Monoclonal Antibody ) in Combination With CHOP Regimen Versus Rituximab in Combination With CHOP Regimen in Treatment-naïve Patients With Diffuse Large B-cell Lymphoma (DLBCL) Unknown status NCT02867566 Phase 3 IBI301 plus CHOP;Rituximab plus CHOP
23 A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells. Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;ARA-C;VP-16;Ciclofosfamide;Doxorubicina;Vincristina
24 Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma Unknown status NCT02617485 Phase 3 Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
25 Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
26 A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma Unknown status NCT03151044 Phase 3 High-dose Epirubicin Combined with CVP ± Rituximab;Standard-dose Epirubicin Combined with CVP ± Rituximab
27 Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions Unknown status NCT02867553 Phase 3 rituximab
28 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
29 A Phase Ⅲ, Multi-center, Randomized, Controlled Study to Compare the Efficiency and Safety of SCT400(Recombinant Chimeric Anti-CD20 Monoclonal Antibody, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated CD20-positive DLBCL Patients Unknown status NCT02772822 Phase 3 SCT400 plus CHOP;Rituximab plus CHOP
30 A Phase III, Open-Label, Prospective, Two-Armed, Multicenter, Randomized, Group Sequential Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study Regimen Versus Observation in Patients With Diffuse Large B-Cell Lymphoma Who Are in Complete Remission After First-Line CHOP-Rituximab (CHOP-R) Therapy Unknown status NCT00322218 Phase 3 Zevalin Therapeutic Regimen
31 Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly Unknown status NCT00725231 Phase 3 chemotherapy
32 Rituximab Maintenance Therapy Versus Observation in Aggressive CD20+ Lymphoma and Mantle Cell Lymphoma - a Prospective Randomized Phase III Trial Unknown status NCT01933711 Phase 3 rituximab
33 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
34 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
35 A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
36 Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
37 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
38 Treatment of Low-Grade Gastric Non-Hodgkin‘s Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study) Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
39 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
40 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
41 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
42 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
43 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
44 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
45 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
46 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
47 High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial Unknown status NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
48 Phase III Study of Combination Chemotherapy in Children With T Cell and Pre-B Cell Non-Hodgkin's Lymphoma Unknown status NCT00003650 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
49 Rituximab + Standard CHOP (R・S-CHOP) vs Rituximab+ Bi-weekly CHOP (R・Bi-CHOP) RCT(Phase II/III) for Stage III/IV Low-grade B-cell Lymphoma (LowBNHL-RS/BiCHOP-P2/3) (JCOG0203) Completed NCT00147121 Phase 2, Phase 3 Rituximab + Standard CHOP;Rituximab + Bi-weekly CHOP
50 Pivotal Phase III Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients With Relapsed Low-Grade or Follicular B-Cell Lymphoma Completed NCT00168740 Phase 3 rituximab

Search NIH Clinical Center for B-Cell Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ibritumomab tiuxetan
Ibrutinib
rituximab

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about B-Cell Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, b-cell

Genetic Tests for B-Cell Lymphoma

Genetic tests related to B-Cell Lymphoma:

# Genetic test Affiliating Genes
1 B-Cell Lymphoma 29

Anatomical Context for B-Cell Lymphoma

MalaCards organs/tissues related to B-Cell Lymphoma:

40
B Cells, T Cells, Bone, Bone Marrow, Breast, Lung, Liver

Publications for B-Cell Lymphoma

Articles related to B-Cell Lymphoma:

(show top 50) (show all 26598)
# Title Authors PMID Year
1
MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. 61 46
18941111 2009
2
Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. 54 61
20442643 2010
3
Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. 54 61
20428773 2010
4
Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a 'transdifferentiation' during the clonal evolution. 54 61
20331331 2010
5
Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. 54 61
20190733 2010
6
IRF4 expression without IRF4 rearrangement is a general feature of primary cutaneous diffuse large B-cell lymphoma, leg type. 54 61
20054341 2010
7
Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. 54 61
20303013 2010
8
Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma. 54 61
20371444 2010
9
Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. 54 61
19889619 2010
10
Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent. 54 61
19714753 2010
11
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. 54 61
19965662 2010
12
Xeroderma pigmentosum skin: an immune privilege site for tumor development. 54 61
19719835 2010
13
Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. 54 61
20122924 2010
14
The expression of Bcl-2 by proliferating cells varies in different categories of B-cell lymphoma. 54 61
20459572 2010
15
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. 54 61
20371683 2010
16
An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma. 54 61
20490333 2010
17
Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. 54 61
20062012 2010
18
Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29b. 54 61
19966860 2010
19
Translocations involving MUM1 are rare in diffuse large B-cell lymphoma. 54 61
18815567 2010
20
CD44 activation in mature B-cell malignancies by a novel recurrent IGH translocation. 54 61
20093404 2010
21
Mechanisms of chromosomal rearrangement in the human genome. 54 61
20158866 2010
22
Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes. 54 61
20174727 2010
23
Deregulation of H3K27 methylation in cancer. 54 61
20104248 2010
24
Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases. 54 61
20093241 2010
25
Cyclins D3 and E go hand in hand with Cdk4/6 in diffuse large B-cell lymphoma. 54 61
20130454 2010
26
Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth: evidence for redundancy with cyclin E. 54 61
20107311 2010
27
CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. 54 61
20004001 2010
28
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. 54 61
20081860 2010
29
Chemoprevention of B-cell lymphomas by inhibition of the Myc target spermidine synthase. 54 61
20103729 2010
30
[Correlation of Bcl-2 with immunological subtype and prognosis in diffuse large B-cell lymphoma.]. 54 61
20302777 2010
31
Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. 54 61
19797725 2010
32
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. 54 61
20054396 2010
33
Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. 54 61
19965678 2010
34
Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. 54 61
19857547 2010
35
REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. 54 61
19289490 2009
36
Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. 54 61
20016842 2009
37
Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy? 54 61
19860620 2009
38
[Construction of expression plasmid for fused idiotypic DNA vaccine of B-cell lymphoma]. 54 61
20030925 2009
39
Long-range oncogenic activation of Igh-c-myc translocations by the Igh 3' regulatory region. 54 61
20010689 2009
40
Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. 54 61
19786664 2009
41
Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. 54 61
19814686 2009
42
Analysis of CXCL9 and CXCR3 expression in a case of intravascular large B-cell lymphoma. 54 61
19766346 2009
43
[Clinicopathologic and immunohistochemical study of intra-abdominal non-Hodgkin B-cell lymphoma occurring in children]. 54 61
20079016 2009
44
[Immunohistochemical study using T-cell lymphoma antibody 1 and CD44 in diagnosis of Burkitt's lymphoma]. 54 61
20079013 2009
45
Gene expression profiling of diffuse large B-cell lymphoma -- comparison depending on the CD21 antigen expression. 54 61
20009432 2009
46
Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. 54 61
19897720 2009
47
Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. 54 61
19917125 2009
48
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. 54 61
19775297 2009
49
Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. 54 61
19734449 2009
50
Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-cells. 54 61
19725825 2009

Variations for B-Cell Lymphoma

Cosmic variations for B-Cell Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM119229461 CDKN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.238C>T p.R80* 9:21971121-21971121 0

Expression for B-Cell Lymphoma

Search GEO for disease gene expression data for B-Cell Lymphoma.

Pathways for B-Cell Lymphoma

GO Terms for B-Cell Lymphoma

Cellular components related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.43 PARP9 MYC MDM2 MALT1 BCL3 BCL10
2 CBM complex GO:0032449 8.62 MALT1 BCL10

Biological processes related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 MYC MDM2 MALT1 BCL6 BCL3
2 cellular response to DNA damage stimulus GO:0006974 9.93 PARP9 MYC CCND1 BCL6 BCL3
3 cytokine-mediated signaling pathway GO:0019221 9.88 MYC IRF4 CCND1 BCL6
4 regulation of apoptotic process GO:0042981 9.88 MALT1 BCL6 BCL3 BCL10
5 positive regulation of transcription, DNA-templated GO:0045893 9.85 REL PARP9 MYC IRF4 BCL3 BCL10
6 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.69 REL BCL3 BCL10
7 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.61 MYC MALT1 BCL10
8 negative regulation of toll-like receptor signaling pathway GO:0034122 9.59 MIR17 IRF4
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.58 MIR20A MIR17 MDM2
10 response to magnesium ion GO:0032026 9.56 MDM2 CCND1
11 cellular response to hypoxia GO:0071456 9.56 MYC MIR17 MDM2 MALAT1
12 response to molecule of bacterial origin GO:0002237 9.55 MALT1 BCL10
13 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.52 MIR20A MIR17
14 negative regulation of transcription by RNA polymerase II GO:0000122 9.5 REL PARP9 MYC MDM2 CCND1 BCL6
15 germinal center formation GO:0002467 9.49 BCL6 BCL3
16 regulation of T cell receptor signaling pathway GO:0050856 9.48 MALT1 BCL10
17 response to fungus GO:0009620 9.46 MALT1 BCL10
18 positive regulation of interleukin-10 biosynthetic process GO:0045082 9.32 IRF4 BCL3
19 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.16 MIR20A MIR17
20 negative regulation of gene expression GO:0010629 9.02 REL PARP9 MIR20A MIR17 MDM2

Molecular functions related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.63 REL MYC IRF4 BCL6 BCL3 BCL11A
2 transcription factor binding GO:0008134 9.02 MYC IRF4 CCND1 BCL3 BCL10
3 kinase activator activity GO:0019209 8.96 MALT1 BCL10

Sources for B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....